Merus Labs International Company Profile (NASDAQ:MSLI)

About Merus Labs International (NASDAQ:MSLI)

Merus Labs International logoMerus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MSLI
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $1.20
  • 200 Day Moving Avg: $0.94
  • 52 Week Range: $0.70 - $1.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 32.50
  • P/E Growth: 0.00
  • Net Margins: -5.18%
  • Return on Equity: -2.51%
  • Return on Assets: -1.32%
  • Debt-to-Equity Ratio: 0.50%
  • Current Ratio: 0.80%
  • Quick Ratio: 0.54%
  • Average Volume: 93,359 shs.
  • Beta: 1.56

Frequently Asked Questions for Merus Labs International (NASDAQ:MSLI)

What is Merus Labs International's stock symbol?

Merus Labs International trades on the NASDAQ under the ticker symbol "MSLI."

How were Merus Labs International's earnings last quarter?

Merus Labs International Inc (NASDAQ:MSLI) posted its quarterly earnings results on Monday, August, 10th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.03. The company earned $7.73 million during the quarter, compared to analysts' expectations of $17.19 million. Merus Labs International had a negative return on equity of 2.51% and a negative net margin of 5.18%. View Merus Labs International's Earnings History.

Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?

6 brokers have issued 1-year price targets for Merus Labs International's shares. Their predictions range from $1.00 to $1.65. On average, they anticipate Merus Labs International's share price to reach $1.35 in the next twelve months. View Analyst Ratings for Merus Labs International.

Who are some of Merus Labs International's key competitors?

Who are Merus Labs International's key executives?

Merus Labs International's management team includes the folowing people:

  • Michael S. Cloutier, Independent Chairman of the Board
  • Barry Fishman, Chief Executive Officer, Director
  • Michael Scott Bumby, Chief Financial Officer
  • Robert McLay, Vice President - Sales and Marketing
  • Frank Rotmann, Vice President and Head of European Operations
  • Robert Bloch M.D., Director
  • Theresa Sheila Firestone, Independent Director
  • David D. Guebert CPA, Independent Director
  • Robert S. Pollock, Independent Director
  • Timothy G. Sorensen, Independent Director

How do I buy Merus Labs International stock?

Shares of Merus Labs International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merus Labs International's stock price today?

One share of Merus Labs International stock can currently be purchased for approximately $1.30.

MarketBeat Community Rating for Merus Labs International (NASDAQ MSLI)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merus Labs International (NASDAQ:MSLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.35 (3.85% upside)
Consensus Price Target History for Merus Labs International (NASDAQ:MSLI)
Price Target History for Merus Labs International (NASDAQ:MSLI)
Analysts' Ratings History for Merus Labs International (NASDAQ:MSLI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Canaccord GenuityDowngradeHold$1.65LowView Rating Details
2/13/2017Bloom BurtonReiterated RatingHoldN/AView Rating Details
12/16/2016ScotiabankReiterated RatingSector Perform$1.75 -> $1.25N/AView Rating Details
12/16/2016Paradigm CapitalReiterated RatingHold$1.60 -> $1.00N/AView Rating Details
12/15/2016CIBCReiterated RatingOutperform -> Neutral$2.40 -> $1.50N/AView Rating Details
11/8/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
6/13/2016WedbushReiterated RatingOutperformN/AView Rating Details
6/13/2016GuggenheimReiterated RatingBuyN/AView Rating Details
2/5/2016MackieReiterated RatingHold$1.90 -> $2.30N/AView Rating Details
2/5/2016Dundee SecuritiesReiterated RatingBuy$3.50 -> $3.60N/AView Rating Details
11/30/2015Royal Bank Of CanadaReiterated RatingSector Outperform$2.90N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Merus Labs International (NASDAQ:MSLI)
Earnings by Quarter for Merus Labs International (NASDAQ:MSLI)
Earnings History by Quarter for Merus Labs International (NASDAQ MSLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q117($0.02)($0.04)$23.18 million$19.53 millionViewListenView Earnings Details
8/10/2015Q3 2015$0.02($0.01)$17.19 million$7.73 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
2017 EPS Consensus Estimate: ($0.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.01)($0.01)($0.01)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171$0.00$0.00$0.00
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)


Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by


Headline Trends for Merus Labs International (NASDAQ:MSLI)
Latest Headlines for Merus Labs International (NASDAQ:MSLI)
DateHeadline logoFinancial Survey: Merus Labs International (NASDAQ:MSLI) and The Medicines (MDCO) - August 14 at 10:10 PM logoMerus Labs International Inc (NASDAQ:MSLI) Receives Consensus Recommendation of "Hold" from Analysts - August 4 at 7:44 AM logoAnalyzing Merus Labs International (MSLI) and The Medicines (MDCO) - July 20 at 8:42 AM logoNorgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma market - July 18 at 6:27 AM logoFeatured Company News - A Majority of Merus Labs' Shareholders Approve Acquisition by Dutch Pharma Major Norgine B.V. - July 14 at 6:37 AM logo$0.01 Earnings Per Share Expected for Merus Labs International Inc. (NASDAQ:MSLI) This Quarter - July 13 at 8:13 AM logoMerus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V. - July 13 at 7:03 AM logoMerus Labs International Inc. Shareholders Approve Plan of Arrangement with Norgine B.V. - July 11 at 2:31 AM logoMerus Labs International Inc. (NASDAQ:MSLI) Given Consensus Recommendation of "Hold" by Analysts - July 10 at 9:55 AM logoPro-Trader Daily: Corporate News Blog - Norgine's Acquisition of Merus Labs Crosses Final Hurdle as Spanish Anti-Trust Agency Okays the Deal - July 7 at 7:34 AM logoMerus Labs International Inc. and Norgine B.V. receive Spanish anti-trust approval of proposed Arrangement - July 3 at 9:40 PM logoBRIEF-Merus Labs International mails letter to shareholders - June 27 at 11:48 PM logoMerus Labs (MSLI) to be Acquired by Norgine B.V. for $1.65/Share - May 12 at 12:12 AM logoBRIEF-Merus Labs announces changes to stock option plan to address ISS recommendation - March 13 at 10:14 AM logo3:28 am Merus Labs responds to media reports suggesting co is exploring strategic alternatives; confirms using Rothschild & Co to evaluate options - March 1 at 6:45 PM logoMerus Labs International's (MSLI) CEO Barry Fishman on Q1 2017 Results - Earnings Call Transcript - February 14 at 8:44 PM logoMerus Labs slumps 15% on fiscal year-end and Q4 results; modest growth in non-GAAP earnings expected - December 15 at 12:22 AM logoMerus Labs Int'l (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M Deal - February 2 at 2:12 PM



Merus Labs International (MSLI) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.